Title |
OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy
|
---|---|
Published in |
Molecular Cancer, February 2015
|
DOI | 10.1186/s12943-015-0307-3 |
Pubmed ID | |
Authors |
Ichiyo Shibahara, Ryuta Saito, Rong Zhang, Masashi Chonan, Takuhiro Shoji, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Masahiko Kanehira, Toshiaki Kikuchi, Takanori So, Takashi Watanabe, Hiroaki Takahashi, Erina Iwabuchi, Yuetsu Tanaka, Yukiko Shibahara, Hironobu Sasano, Naoto Ishii, Teiji Tominaga |
Abstract |
Glioblastoma is the most malignant human brain tumor and has a dismal prognosis; however, some patients show long-term survival. The interaction between the costimulatory molecule OX40 and its ligand OX40L generates key signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity. In this present study, we explored whether OX40 signaling is responsible for antitumor adaptive immunity against glioblastoma and also established therapeutic antiglioma vaccination therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 92 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 24 | 26% |
Researcher | 21 | 22% |
Student > Doctoral Student | 10 | 11% |
Student > Bachelor | 8 | 9% |
Student > Master | 5 | 5% |
Other | 9 | 10% |
Unknown | 17 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 27% |
Agricultural and Biological Sciences | 14 | 15% |
Biochemistry, Genetics and Molecular Biology | 11 | 12% |
Immunology and Microbiology | 11 | 12% |
Neuroscience | 4 | 4% |
Other | 8 | 9% |
Unknown | 21 | 22% |